FATE
FATE THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$2.53
+0.40%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.27
- Revenue estimate
- $1.2M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.25
- EPS estimate
- -$0.25
- Revenue actual
- $2.1M
- Revenue estimate
- $1.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +7.0%
- Revenue beats (12Q)
- 10
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.17
- PT range
- $3.50 – $8.00
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.25 | -$0.25 | Beat 1.44% | $2.1M |
| May 13, 2026 | -$0.29 | -$0.26 | Beat 10.34% | $1.3M |
| Feb 26, 2026 | -$0.30 | -$0.27 | Beat 9.16% | $1.4M |
| Nov 13, 2025 | -$0.29 | -$0.27 | Beat 6.90% | $1.7M |
| Aug 12, 2025 | -$0.35 | -$0.29 | Beat 17.14% | $1.9M |
| Mar 5, 2025 | -$0.44 | -$0.31 | Beat 29.55% | $1.9M |
| Aug 13, 2024 | -$0.47 | -$0.33 | Beat 29.79% | $6.8M |
| May 9, 2024 | -$0.47 | -$0.47 | In line | $1.9M |
| Feb 26, 2024 | -$0.57 | -$0.45 | Beat 21.05% | $1.7M |
| May 3, 2023 | -$0.55 | -$0.19 | Beat 65.45% | $59.0M |
| Feb 28, 2023 | -$0.86 | -$0.58 | Beat 32.56% | $44.4M |
| Nov 3, 2022 | -$0.93 | -$0.86 | Beat 7.53% | $15.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026